AstraZeneca
AZN
$69.95
Share price
-1.14%
Change (1 day)
-11.32%
Change (1 year)
Categories
Market capitalization of AstraZeneca (AZN)
Market cap: $217.06 Billion USD
As of June 2025 AstraZeneca has a market cap of $217.06 Billion USD. This makes AstraZeneca the world's 61th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AstraZeneca from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | $217.06 B | 5.66% |
| 2024 | $205.44 B | -1.59% |
| 2023 | $208.77 B | -0.77% |
| 2022 | $210.38 B | 15.94% |
| 2021 | $181.46 B | 38.54% |
| 2020 | $130.98 B | 0.09% |
| 2019 | $130.87 B | 38.6% |
| 2018 | $94.42 B | 8.37% |
| 2017 | $87.12 B | 26.34% |
| 2016 | $68.96 B | -20.23% |
| 2015 | $86.45 B | -3.47% |
| 2014 | $89.56 B | 20.86% |
| 2013 | $74.10 B | 26.41% |
| 2012 | $58.62 B | -2.01% |
| 2011 | $59.82 B | -8.08% |
| 2010 | $65.08 B | -4.44% |
| 2009 | $68.10 B | 14.68% |
| 2008 | $59.39 B | -4.81% |
| 2007 | $62.38 B | -23.95% |
| 2006 | $82.03 B | 5.1% |
| 2005 | $78.05 B | 30.47% |
| 2004 | $59.82 B | -26.96% |
| 2003 | $81.90 B | 35.82% |
| 2002 | $60.30 B | -25.85% |
| 2001 | $81.33 B | -10.57% |
| 2000 | $90.94 B | 22.66% |
| 1999 | $74.14 B | 73.95% |
| 1998 | $42.62 B | 24.76% |
| 1997 | $34.16 B | 28.82% |
| 1996 | $26.52 B |
End of Day market cap according to different sources
On Jun 21st, 2025 the market cap of AstraZeneca was reported to be:
$216.93 Billion USD
$217.06 Billion USD
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | $95.36 B | -56.07% | 🇺🇸 USA |
 Pfizer PFE | $136.27 B | -37.22% | 🇺🇸 USA |
 Merck MRK | $198.52 B | -8.54% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $77.66 B | -64.22% | 🇬🇧 UK |
 Sanofi SNY | $116.54 B | -46.31% | 🇫🇷 France |
 Eli Lilly LLY | $684.73 B | 215.44% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $360.40 B | 66.03% | 🇺🇸 USA |
 Abbott Laboratories ABT | $231.38 B | 6.59% | 🇺🇸 USA |
 Biogen BIIB | $18.61 B | -91.42% | 🇺🇸 USA |
 Novartis NVS | $229.16 B | 5.57% | 🇨🇭 Switzerland |